• a bridge between China and advanced technology companies in the US and EU
• specializes in the development of high-quality biotechnology, pharmaceutical and diagnostic products in China
• provides all aspects of partnering activities i.e. fund raising, due diligence, drug/device development and licensing or M&A negotiations
• headquartered in the U.S.
•Operates under standard U.S. legal terms and conditions
•Strong understanding of the U.S. and China markets
•Science that stands apart from the pack
•Novel underlying therapeutic mechanisms
•Significant potential for synergy with existing standards of care
•Persuasive conceptual and mechanistic context
•Strong preliminary data
•Strong leadership of the in-licensed asset company
•Sound development strategy
•Reimbursement guidance and need
•Strong potential for market penetration
•Proximity to clinical trials
•Emphasis on co-development opportunities
•Immuno-oncology therapeutics
•Autoimmune diseases
•Anti-infectives
•Cardiovascular diseases
•Medical devices